Page 2 - Elix Does Not Undertake To Publicly Update Or Review Any Forward Looking Statements Past Performance Cannot Be Relied On Asa Guide Future Readers Should Read This Announcement Together With Our Material Risks News Today : Breaking News, Live Updates & Top Stories | Vimarsana
MELBOURNE, Australia, March 9, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 - 13 March 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a "Game Changing" oral session. Game Changing sessions are reserved for Phase III trials or other developments that the EAU's Scientific Congress Office believes will have a large impact on daily practice. In addition, presentations will report on the potential utility of TLX250-CDx in urothelial carcinoma or bladder cancer (ZiPUP study, ClinicalTrials.gov Identifier: NCT05046665); and a preclinical evaluation of a
MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021.[1] The aim of this project was to create and validate a generator-based theranostic compound for urologic oncology targeting PSMA[2] and utilising the beta-emitting isotope rhenium-188 (188Re). The outcomes from the research project - which included a pre-clinical and first-in-human evaluation - have been published in the latest issue of the Journal of Nuclear Medicine.[3] The project has resulted in new intellectual property and a translational data package that may be used to advance this compound into a Phase I clinical trial. Telix is now progressing discussions regarding the further development of the compound with the goal of spinning-out this program into an innovative new compan